Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats

Pharmacological Research

Volumn 61, Issue 4, 2010, Pages 321-328

  De Filippis, D ^a   D'Amico, A ^a   Cipriano, M ^a   Petrosino, S ^b   Orlando, P ^c   Di Marzo, V ^b   Iuvone, T ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

Author keywords

Angiogenesis; CB1 and CB2 receptors; Chronic inflammation; Endocannabinoids; Granuloma formation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ARACHIDONOYLSEROTONIN; CANNABINOID RECEPTOR; CARRAGEENAN; CD31 ANTIGEN; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; HEMOGLOBIN; PALMIDROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE LEVEL; WESTERN BLOTTING; WISTAR RAT;

AMIDOHYDROLASES; ANIMALS; ANTIGENS, CD31; ARACHIDONIC ACIDS; CARRAGEENAN; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; GRANULOMA; HEMOGLOBINS; INFLAMMATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; PALMITIC ACIDS; PHOSPHOLIPASE D; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; SEROTONIN; TRPV CATION CHANNELS;

EID: 77649342807     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.11.005     Document Type: Article

References (55)

1. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
2. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74 (1997) 129-180 [review]
3. Matias I., Pochard P., Orlando P., Salzet M., Pestel J., and Di Marzo V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269 (2002) 3771-3778
4. Rossato M., Ion Popa F., Ferigo M., Clari G., and Foresta C. Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. J Clin Endocrinol Metab 90 (2005) 984-991
5. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
6. Izzo A.A. Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol 142 (2004) 1201-1202 [review]
7. Di Marzo V., and Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot Essent Fatty Acids 53 (1995) 1-11 [review]
8. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
9. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
10. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 (1995) 89-97
11. Steffens M., Zentner J., Honegger J., and Feuerstein T.J. Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. Biochem Pharmacol 69 (2005) 169-178
12. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275 (2000) 605-612
13. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res (2009) [review]
14. Bifulco M. The endocannabinoid system: from biology to therapy. Pharmacol Res 60 (2009) 75-76 [review]
15. Bisogno T., Sepe N., De Petrocellis L., Mechoulam R., and Di Marzo V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 239 (1997) 473-479
16. Re G., Barbero R., Miolo A., and Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 173 (2007) 21-30 [review]
17. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67 (2005) 15-19
18. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152 (2007) 576-582 [review]
19. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358 (2001) 249-255
20. De Petrocellis L., Davis J.B., and Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506 (2001) 253-256
21. Costa B., Comelli F., Bettoni I., Colleoni M., and Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain (2008)
22. Karanian D.A., and Bahr B.A. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med 6 (2006) 677-984 [review]
23. Di Marzo V., and Izzo A.A. Endocannabinoid overactivity and intestinal inflammation. Gut 55 (2006) 1373-1376
24. Centonze D., Finazzi-Agrò A., Bernardi G., and Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28 (2007) 180-187 [review]
25. van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63 (2006) 1410-1424
26. Iuvone T., De Filippis D., Di Spiezio Sardo A., D'Amico A., Simonetti S., Sparice S., et al. Selective CB2 up-regulation in women affected by endometrial inflammation. J Cell Mol Med 12 (2008) 661-670
27. De Filippis D., D'Amico A., Cinelli M.P., Esposito G., Di Marzo V., and Iuvone T. Adelmidrol, a palmitoylethanolamide analog, reduces chronic inflammation in a carrageenin-granuloma model in rats. J Cell Mol Med (2008)
28. De Filippis D., Russo A., De Stefano D., Maiuri M.C., Esposito G., Cinelli M.P., et al. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. J Mol Med 85 (2007) 635-645
29. Grimaldi P., Orlando P., Di Siena S., Lolicato F., Petrosino S., Bisogno T., et al. The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci USA 106 (2009) 11131-11136
30. Drapier J.C., and Petit J.F. Development of antitumor activity in LPS-stimulated mouse granuloma macrophages. Regulation by eicosanoids. Inflammation 10 (1986) 195-204
31. Colville-Nash P.R., Alam C.A., Appleton I., Brown J.R., Seed M.P., and Willoughby D.A. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. J Pharmacol Exp Ther 274 (1995) 1463-1472
32. Risau W. Mechanisms of angiogenesis. Nature 386 April (6626) (1997) 671-674 [review]
33. Jackson J.R., Bolognese B., Kircher C.H., Marshall L.A., and Winkler J.D. Modulation of angiogenesis in a model of chronic inflammation. Inflamm Res 46 Suppl. 2 (1997) S129-S130
34. Kobayashi S.D., Voyich J.M., Braughton K.R., Whitney A.R., Nauseef W.M., Malech H.L., et al. Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. J Immunol 172 (2004) 636-643
35. Tripp C.S., Needleman P., Kassab J.T., and Weinstock J.V. Macrophages isolated from liver granulomas of murine Schistosoma mansoni synthesize predominantly TxA2 during the acute and chronic phases of infection. J Immunol 140 (1988) 3140-3143
36. Martìn-Padura I., De Castellarnau C., Uccini S., Pilozzi E., Natali P.G., Nicotra M.R., et al. Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J Pathol 175 (1995) 51-57
37. Russo A., Russo G., Peticca M., Pietropaolo C., Di Rosa M., and Iuvone T. Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5. Br J Pharmacol 145 (2005) 24-33
38. Brown J.F., Chafee K.A., and Tepperman B.L. Role of mast cells, neutrophils and nitric oxide in endotoxin-induced damage to the neonatal rat colon. Br J Pharmacol 123 (1998) 31-38
39. Maiuri M.C., Tajana G., Iuvone T., De Stefano D., Mele G., Ribecco M.T., et al. Nuclear factor-kappaB regulates inflammatory cell apoptosis and phagocytosis in rat carrageenin-sponge implant model. Am J Pathol 165 (2004) 115-126
40. Esposito G., Iuvone T., Savani C., Scuderi C., De Filippis D., Papa M., et al. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther 322 (2007) 1144-1152
41. Jhaveri M.D., Richardson D., Robinson I., Garle M.J., Patel A., Sun Y., et al. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55 (2008) 85-93
42. Goparaju S.K., Ueda N., Yamaguchi H., and Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422 (1998) 69-73
43. Di Marzo V., Bisogno T., Sugiura T., Melck D., and De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331 (1998) 15-19
44. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 322 (2007) 1137-1143
45. Mazzari S., Canella R., Petrelli L., Marcolongo G., and Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 300 (1996) 227-236
46. Conti S., Costa B., Colleoni M., Parolaro D., and Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135 (2002) 181-187
47. Samson M.T., Small-Howard A., Shimoda L.M., Koblan-Huberson M., Stokes A.J., and Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170 (2003) 4953-4962
48. Small-Howard A.L., Shimoda L.M., Adra C.N., and Turner H. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J 388 (2005) 465-473
49. Ständer S., Moormann C., Schumacher M., Buddenkotte J., Artuc M., Shpacovitch V., et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 13 (2004) 129-139
50. Maione S., De Petrocellis L., de Novellis V., Morello A.S., Petrosino S., Palazzo E., et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150 (2007) 766-781
51. D'Argenio G., Petrosino S., Gianfrani C., Valenti M., Scaglione G., Grandone I., et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 85 (2007) 523-530
52. Costa B, Bettoni I, Petrosino S, Comelli F, Giagnoni G, Di Marzo V. Effect of N-arachidonoyl-serotonin, a dual fatty acid amide hydrolase/TRPV1 blocker, on carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol Res; submitted for publication.
53. Maccarrone M., Fiori A., Bari M., Granata F., Gasperi V., De Stefano M.E., et al. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb Haemost 95 (2006) 117-127
54. De Filippis D., and Iuvone T. A glance over the cannabinoid machinery to design new anti-angiogenic compounds. Mini-Rev Med Chem 9 (2009)
55. Skaper S.D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 93 (1996) 3984-3989